Please select the option that best describes you:
When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?
How will you translate treatment recommendations from older studies to the new staging system?
Answer from: Radiation Oncologist at Academic Institution
Agree with the previous comment. Current adjuvant RT for stage I and II are based on mainly histopathological classification (PORTEC-I/II). However, the recent publication of PORTEC-4a (Horeweg et al., PMID 37487144) for stage I/II showed molecular classification predicts response for stage I/II. Mo...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I think, to some degree, we are already using the new FIGO system to make clinical decisions.
Answer from: Radiation Oncologist at Academic Institution
We are not routinely using it at the current time and are unlikely to change until NCCN adopts, which (IMO) will be dependent on prospective data from PORTEC-4a being published. What Dr. @Kim linked is a retrospective classification of PORTEC-1/2 patients which, while not technically prospectiv...